131 related articles for article (PubMed ID: 20676796)
1. Secondary prevention for coronary artery disease: are we following the guidelines?
Syed IA; Riaz A; Ryan A; Reilly MO
Ir J Med Sci; 2010 Dec; 179(4):535-7. PubMed ID: 20676796
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of drug utilization for secondary prevention in coronary artery disease.
Apikoglu Rabus S; Izzettin FV; Sancar M; Karakaya O; Kargin R; Yakut C
Pharm World Sci; 2008 Dec; 30(6):753-8. PubMed ID: 18563622
[TBL] [Abstract][Full Text] [Related]
4. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Sharma KK; Gupta R; Agrawal A; Roy S; Kasliwal A; Bana A; Tongia RK; Deedwania PC
Vasc Health Risk Manag; 2009; 5():1007-14. PubMed ID: 19997570
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.
Underwood P; Beck P
Qual Saf Health Care; 2002 Sep; 11(3):230-2. PubMed ID: 12486986
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease.
Sharma KK; Mathur M; Gupta R; Guptha S; Roy S; Khedar RS; Gupta N; Gupta R
Indian Heart J; 2013; 65(3):250-5. PubMed ID: 23809376
[TBL] [Abstract][Full Text] [Related]
8. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Yahia DH; Pereg D; Lishner M; Elis A
Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
[TBL] [Abstract][Full Text] [Related]
9. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
11. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
[TBL] [Abstract][Full Text] [Related]
12. Use of recommended medications after myocardial infarction in Austria.
Winkelmayer WC; Bucsics AE; Schautzer A; Wieninger P; Pogantsch M;
Eur J Epidemiol; 2008; 23(2):153-62. PubMed ID: 18064529
[TBL] [Abstract][Full Text] [Related]
13. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
14. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study.
Ivers NM; Schwalm JD; Jackevicius CA; Guo H; Tu JV; Natarajan M
Can J Cardiol; 2013 Nov; 29(11):1408-14. PubMed ID: 23816280
[TBL] [Abstract][Full Text] [Related]
15. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
Abdu FA; Liu L; Mohammed AQ; Xu B; Yin G; Xu S; Xu Y; Che W
J Cardiovasc Pharmacol; 2020 Dec; 76(6):678-683. PubMed ID: 33284169
[TBL] [Abstract][Full Text] [Related]
16. Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
Kumbhani DJ; Fonarow GC; Cannon CP; Hernandez AF; Peterson ED; Peacock WF; Laskey WK; Deedwania P; Grau-Sepulveda M; Schwamm LH; Bhatt DL;
Am J Med; 2015 Apr; 128(4):426.e1-9. PubMed ID: 25433302
[TBL] [Abstract][Full Text] [Related]
17. ACE up the sleeve - are vascular patients medically optimized?
Coveney AP; O'Brien GC; Fulton GJ
Vasc Health Risk Manag; 2011 Jan; 7():15-21. PubMed ID: 21339909
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
[TBL] [Abstract][Full Text] [Related]
19. Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit.
Sharma KK; Guptha S; Gupta R
J Assoc Physicians India; 2012 Apr; 60():28-30. PubMed ID: 23029739
[TBL] [Abstract][Full Text] [Related]
20. Underuse of cardioprotective medications in patients prior to acute myocardial infarction.
Miller RR; Li YF; Sun H; Kopjar B; Sales AE; Piñeros SL; Fihn SD
Am J Cardiol; 2003 Jul; 92(2):209-11. PubMed ID: 12860227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
